Anlotinib
Anlotinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, fibroblast growth factor receptor 1, and vascular endothelial growth factor receptor 1.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
319 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 7 | 16 | 1 | — | 1 | 22 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 12 | 2 | — | 2 | 15 |
| Colorectal neoplasms | D015179 | 2 | 9 | 2 | — | — | 10 | ||
| Triple negative breast neoplasms | D064726 | 2 | 5 | 1 | — | — | 8 | ||
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 6 | 1 | — | 2 | 8 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 6 | 1 | — | — | 7 |
| Endometrial neoplasms | D016889 | EFO_0004230 | 2 | 6 | 1 | — | — | 7 | |
| Uterine cervical neoplasms | D002583 | 2 | 2 | 1 | — | 1 | 5 | ||
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 5 | 1 | — | — | 5 | |
| Biliary tract neoplasms | D001661 | C24.9 | — | 1 | 1 | — | — | 2 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | C34.90 | 4 | 10 | — | — | 3 | 14 | |
| Esophageal squamous cell carcinoma | D000077277 | — | 8 | — | — | 1 | 9 | ||
| Glioblastoma | D005909 | EFO_0000515 | 2 | 7 | — | — | — | 7 | |
| Nasopharyngeal neoplasms | D009303 | 2 | 7 | — | — | — | 7 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 6 | — | — | — | 6 |
| Immunotherapy | D007167 | 1 | 5 | — | — | — | 5 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 3 | — | — | — | 5 |
| Adenocarcinoma | D000230 | 2 | 3 | — | — | 1 | 5 | ||
| Female genital neoplasms | D005833 | 1 | 4 | — | — | 1 | 5 | ||
| Neoplasms by site | D009371 | — | 4 | — | — | — | 4 |
Show 51 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | C90.0 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ANLOTINIB |
| INN | catequentinib |
| Description | Anlotinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, fibroblast growth factor receptor 1, and vascular endothelial growth factor receptor 1. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1058156-90-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4303201 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | GKF8S4C432 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KDR
KDR
FLT4
FLT4
FGFR1
FGFR1
FLT1
FLT1
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,917 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
152 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more